23andMe Holding Co. (ME) NASDAQ
0.61
+0.6063(+100.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.61
+0.6063(+100.00%)
Currency In USD
| Previous Close | 0.61 |
| Open | 0.61 |
| Day High | 0.61 |
| Day Low | 0.61 |
| 52-Week High | 12.76 |
| 52-Week Low | 0.48 |
| Volume | 29.75M |
| Average Volume | 4.1M |
| Market Cap | 15.31M |
| PE | -0.03 |
| EPS | -17.39 |
| Moving Average 50 Days | 1.68 |
| Moving Average 200 Days | 4.38 |
| Change | 0.61 |
Data not available
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
GlobeNewswire Inc.
Mar 26, 2025 10:57 PM GMT
Receives Court Approval for First Day Motions to Support Ongoing Business OperationsSAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), a leading human genetics and biotechnology company,
23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process
GlobeNewswire Inc.
Mar 24, 2025 3:08 AM GMT
Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
GlobeNewswire Inc.
Mar 21, 2025 11:30 AM GMT
Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levelsSAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics co